IQVIA Holdings Inc. (IQV) EPS Diluted: 7.84
Is IQVIA Holdings Inc.’s EPS diluted high or low?
IQVIA Holdings Inc.'s EPS diluted of 7.84 is 35% above its 5-year average of 5.79, near the high end of its 5-year range (1.43–7.84).
2.28% above its 12-month average of 7.67.
IQV EPS Diluted Chart
IQV Average EPS Diluted Chart
IQV Current vs Average EPS Diluted Chart
IQV EPS Diluted Metrics
EPS DILUTED
7.84
EPS DILUTED AVG TTM
7.67
EPS DILUTED AVG 3Y
7.08
EPS DILUTED AVG 5Y
5.79
EPS DILUTED AVG 10Y
4.24
EPS DILUTED AVG 15Y
3.48
EPS DILUTED AVG 20Y
3.48
CURRENT VS TTM AVG
+2.28%
CURRENT VS 3Y AVG
+10.66%
CURRENT VS 5Y AVG
+35.48%
CURRENT VS 10Y AVG
+84.91%
CURRENT VS 15Y AVG
+125.29%
CURRENT VS 20Y AVG
+125.29%
IQVIA Holdings Inc. EPS Diluted Formula & Definition
EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. EPS Diluted FAQ
- What is the EPS diluted for IQVIA Holdings Inc. (IQV)?
- The EPS diluted for IQV stock is 7.84.
- Is IQVIA Holdings Inc.'s EPS diluted high or low?
- IQVIA Holdings Inc.'s EPS diluted of 7.84 is 35% above its 5-year average of 5.79, near the high end of its 5-year range (1.43–7.84).
- What is the TTM average EPS diluted for IQVIA Holdings Inc. (IQV)?
- The TTM average EPS diluted for IQV stock is 7.67.
- What is the 3Y average EPS diluted for IQVIA Holdings Inc. (IQV)?
- The 3Y average EPS diluted for IQV stock is 7.08.
- What is the 5Y average EPS diluted for IQVIA Holdings Inc. (IQV)?
- The 5Y average EPS diluted for IQV stock is 5.79.
- What is the 10Y average EPS diluted for IQVIA Holdings Inc. (IQV)?
- The 10Y average EPS diluted for IQV stock is 4.24.
- What is the 15Y average EPS diluted for IQVIA Holdings Inc. (IQV)?
- The 15Y average EPS diluted for IQV stock is 3.48.
- What is the 20Y average EPS diluted for IQVIA Holdings Inc. (IQV)?
- The 20Y average EPS diluted for IQV stock is 3.48.
IQVIA Holdings Inc. EPS Diluted History
| DATE | EPS DILUTED |
|---|---|
| 2025-12-31 | 7.84 |
| 2024-12-31 | 7.49 |
| 2023-12-31 | 7.29 |
| 2022-12-31 | 5.72 |
| 2021-12-31 | 4.95 |
| 2020-12-31 | 1.43 |
| 2019-12-31 | 0.96 |
| 2018-12-31 | 1.24 |
| 2017-12-31 | 5.88 |
| 2016-12-31 | 0.76 |
| 2015-12-31 | 3.08 |
| 2014-12-31 | 2.72 |
| 2013-12-31 | 1.77 |
| 2012-12-31 | 1.39 |
| 2011-12-31 | 1.90 |
| 2010-12-31 | 1.26 |
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib